JP2018172384A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018172384A5 JP2018172384A5 JP2018087413A JP2018087413A JP2018172384A5 JP 2018172384 A5 JP2018172384 A5 JP 2018172384A5 JP 2018087413 A JP2018087413 A JP 2018087413A JP 2018087413 A JP2018087413 A JP 2018087413A JP 2018172384 A5 JP2018172384 A5 JP 2018172384A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- tyr
- thr
- glu
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020192994A JP7481236B2 (ja) | 2012-05-30 | 2020-11-20 | 会合化した抗原を消失させる抗原結合分子 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012123782 | 2012-05-30 | ||
| JP2012123782 | 2012-05-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014518714A Division JPWO2013180201A1 (ja) | 2012-05-30 | 2013-05-30 | 会合化した抗原を消失させる抗原結合分子 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020192994A Division JP7481236B2 (ja) | 2012-05-30 | 2020-11-20 | 会合化した抗原を消失させる抗原結合分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018172384A JP2018172384A (ja) | 2018-11-08 |
| JP2018172384A5 true JP2018172384A5 (https=) | 2019-02-07 |
| JP7016769B2 JP7016769B2 (ja) | 2022-02-07 |
Family
ID=49673388
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014518714A Withdrawn JPWO2013180201A1 (ja) | 2012-05-30 | 2013-05-30 | 会合化した抗原を消失させる抗原結合分子 |
| JP2018087413A Active JP7016769B2 (ja) | 2012-05-30 | 2018-04-27 | 会合化した抗原を消失させる抗原結合分子 |
| JP2020192994A Active JP7481236B2 (ja) | 2012-05-30 | 2020-11-20 | 会合化した抗原を消失させる抗原結合分子 |
| JP2022120135A Pending JP2022141941A (ja) | 2012-05-30 | 2022-07-28 | 会合化した抗原を消失させる抗原結合分子 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014518714A Withdrawn JPWO2013180201A1 (ja) | 2012-05-30 | 2013-05-30 | 会合化した抗原を消失させる抗原結合分子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020192994A Active JP7481236B2 (ja) | 2012-05-30 | 2020-11-20 | 会合化した抗原を消失させる抗原結合分子 |
| JP2022120135A Pending JP2022141941A (ja) | 2012-05-30 | 2022-07-28 | 会合化した抗原を消失させる抗原結合分子 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20150353630A1 (https=) |
| EP (2) | EP2857419B1 (https=) |
| JP (4) | JPWO2013180201A1 (https=) |
| DK (1) | DK2857419T3 (https=) |
| ES (1) | ES2856272T3 (https=) |
| WO (1) | WO2013180201A1 (https=) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| KR101680906B1 (ko) | 2007-09-26 | 2016-11-30 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| AU2011283694B2 (en) | 2010-07-29 | 2017-04-13 | Xencor, Inc. | Antibodies with modified isoelectric points |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| TWI687439B (zh) | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | 異源二聚化多胜肽 |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| EP2752200B1 (en) | 2011-09-30 | 2023-11-01 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule inducing immune response to target antigen |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| KR20230143201A (ko) | 2011-11-30 | 2023-10-11 | 추가이 세이야쿠 가부시키가이샤 | 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약 |
| SG11201404751UA (en) | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| WO2013180200A1 (ja) | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | 標的組織特異的抗原結合分子 |
| SG10201709559PA (en) | 2012-08-24 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| ES2876009T3 (es) | 2012-12-27 | 2021-11-11 | Chugai Pharmaceutical Co Ltd | Polipéptido heterodimerizado |
| KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| WO2014113510A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| EP2970486B1 (en) | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| CN105246914B (zh) | 2013-04-02 | 2021-08-27 | 中外制药株式会社 | Fc区变体 |
| GB201403775D0 (en) * | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| EP3699195A3 (en) | 2014-03-28 | 2020-11-04 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
| EP3194449A1 (en) * | 2014-07-24 | 2017-07-26 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| PE20171324A1 (es) | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| CA2972393A1 (en) | 2015-02-27 | 2016-09-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| CA3007030A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| AR107078A1 (es) | 2015-12-18 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| JP7010854B2 (ja) | 2016-06-14 | 2022-01-26 | ゼンコア インコーポレイテッド | 二重特異性チェックポイント阻害剤抗体 |
| KR102376582B1 (ko) | 2016-06-17 | 2022-03-18 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체 및 사용 방법 |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| CN109715663B (zh) | 2016-06-28 | 2022-11-25 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
| HRP20260151T1 (hr) | 2016-08-02 | 2026-03-27 | Visterra, Inc. | Modificirani polipeptidi i njihova uporaba |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| MY203000A (en) | 2016-10-14 | 2024-06-01 | Xencor Inc | Il15/il15r� heterodimeric fc-fusion proteins |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
| IL268959B2 (en) | 2017-02-28 | 2025-01-01 | Seagen Inc | Cystine-mutated antibodies, compositions containing them and uses thereof |
| WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| KR20200014379A (ko) * | 2017-06-05 | 2020-02-10 | 얀센 바이오테크 인코포레이티드 | 비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질 |
| WO2019006472A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
| US11059892B2 (en) * | 2017-08-11 | 2021-07-13 | Research Development Foundation | Engineered antibody Fc variants for enhanced serum half life |
| AU2018345807B2 (en) | 2017-10-06 | 2025-02-06 | Novo Nordisk A/S | Methods of detecting transthyretin |
| CU24731B1 (es) | 2017-10-06 | 2025-01-15 | Prothena Biosciences Ltd | Anticuerpos anti-transtiretina |
| JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体 |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| EP4640703A3 (en) | 2017-11-14 | 2026-04-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibodies and methods of use |
| PE20211453A1 (es) | 2017-11-29 | 2021-08-05 | Prothena Biosciences Ltd | Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| IL275426B2 (en) | 2017-12-19 | 2025-03-01 | Xencor Inc | Engineered il-2 fc fusion proteins |
| CN112119090B (zh) | 2018-03-15 | 2023-01-13 | 中外制药株式会社 | 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法 |
| CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| SG11202010163QA (en) | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| EP3781598A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| KR102259473B1 (ko) | 2018-08-10 | 2021-06-02 | 추가이 세이야쿠 가부시키가이샤 | 항cd137 항원 결합 분자 및 그의 사용 |
| AU2019355971B2 (en) | 2018-10-03 | 2025-05-08 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
| CA3132185A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| US20220213140A1 (en) | 2019-04-10 | 2022-07-07 | Chugai Seiyaku Kabushiki Kaisha | Method for purifying fc region-modified antibody |
| EP4696320A2 (en) | 2019-05-15 | 2026-02-18 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibody |
| AU2020403913B2 (en) | 2019-12-18 | 2024-10-10 | F. Hoffmann-La Roche Ag | Bispecific anti-CCL2 antibodies |
| UA128549C2 (uk) | 2019-12-27 | 2024-08-07 | Чугаі Сейяку Кабусікі Кайся | Антитіло до ctla-4 та його застосування |
| TWI895351B (zh) | 2020-02-12 | 2025-09-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| WO2022044248A1 (ja) | 2020-08-28 | 2022-03-03 | 中外製薬株式会社 | ヘテロ二量体Ｆｃポリペプチド |
| US11739144B2 (en) | 2021-03-09 | 2023-08-29 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CLDN6 |
| EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| AU2022295067A1 (en) | 2021-06-18 | 2023-12-21 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
| TWI879694B (zh) | 2021-06-25 | 2025-04-01 | 日商中外製藥股份有限公司 | 抗ctla-4抗體的用途 |
| AR126220A1 (es) | 2021-06-25 | 2023-09-27 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-ctla-4 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JPH0636741B2 (ja) * | 1989-11-08 | 1994-05-18 | 帝人株式会社 | ヒト・プロテインｃの分離方法 |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
| JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
| WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
| DE69535243T2 (de) | 1994-07-13 | 2007-05-10 | Chugai Seiyaku K.K. | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US7183387B1 (en) * | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
| SI1706424T1 (sl) | 2004-01-12 | 2010-01-29 | Applied Molecular Evolution | Variante fc regij |
| US20050260711A1 (en) | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
| CN101163498B (zh) * | 2004-06-18 | 2011-10-05 | 诺华疫苗和诊断公司 | 用于诊断汉他病毒感染的方法和试剂 |
| AU2005274905B2 (en) | 2004-08-04 | 2010-12-23 | Mentrik Biotech, Llc | Variant Fc regions |
| CA2576405A1 (en) * | 2004-08-11 | 2006-02-16 | Mitsubishi Chemical Corporation | Antibody and utilization of the same |
| EP1778726A4 (en) | 2004-08-16 | 2009-03-18 | Medimmune Inc | INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY |
| AU2005285347A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| AU2005304624B2 (en) * | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006105338A2 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
| PL2573114T3 (pl) | 2005-08-10 | 2016-10-31 | Identyfikacja i inżynieria przeciwciał z wariantami regionów FC oraz sposoby ich stosowania | |
| WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| CN104761637B (zh) * | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| CA2659574C (en) | 2006-08-02 | 2017-04-25 | The Uab Research Foundation | Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity |
| WO2008081008A1 (en) | 2007-01-05 | 2008-07-10 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| US8940872B2 (en) * | 2007-07-06 | 2015-01-27 | Tokyo Metropolitan Institute Of Medical Science | Antibody binding specifically to TDP-43 aggregate |
| HRP20150279T1 (hr) | 2007-12-26 | 2015-05-08 | Xencor, Inc. | Fc inaäśice s promijenjenim vezanjem na fcrn |
| KR102057826B1 (ko) * | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| JP5913980B2 (ja) | 2008-10-14 | 2016-05-11 | ジェネンテック， インコーポレイテッド | 免疫グロブリン変異体及びその用途 |
| JP5807300B2 (ja) * | 2008-11-18 | 2015-11-10 | 株式会社シノテスト | 試料中のｃ反応性蛋白質の測定方法及び測定試薬 |
| WO2011108714A1 (ja) * | 2010-03-04 | 2011-09-09 | 中外製薬株式会社 | 抗体定常領域改変体 |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| EP2647706B1 (en) * | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| TW201817744A (zh) * | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| RU2014117505A (ru) * | 2011-09-30 | 2015-11-10 | Чугаи Сейяку Кабусики Кайся | Антигенсвязывающая молекула для ускорения удаления антигенов |
| KR20230143201A (ko) * | 2011-11-30 | 2023-10-11 | 추가이 세이야쿠 가부시키가이샤 | 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약 |
| EP3738980A1 (en) * | 2012-02-24 | 2020-11-18 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via fc gamma riib |
-
2013
- 2013-05-30 EP EP13796975.4A patent/EP2857419B1/en active Active
- 2013-05-30 EP EP21151149.8A patent/EP3892638A1/en active Pending
- 2013-05-30 ES ES13796975T patent/ES2856272T3/es active Active
- 2013-05-30 WO PCT/JP2013/064979 patent/WO2013180201A1/ja not_active Ceased
- 2013-05-30 JP JP2014518714A patent/JPWO2013180201A1/ja not_active Withdrawn
- 2013-05-30 US US14/404,051 patent/US20150353630A1/en not_active Abandoned
- 2013-05-30 DK DK13796975.4T patent/DK2857419T3/da active
-
2018
- 2018-04-27 JP JP2018087413A patent/JP7016769B2/ja active Active
-
2020
- 2020-11-20 JP JP2020192994A patent/JP7481236B2/ja active Active
-
2021
- 2021-01-08 US US17/144,342 patent/US20210122812A1/en active Pending
-
2022
- 2022-07-28 JP JP2022120135A patent/JP2022141941A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018172384A5 (https=) | ||
| JP2021042225A5 (https=) | ||
| KR102504884B1 (ko) | Sftsv에 결합 가능한 나노 항체 및 이의 응용 | |
| Lewis et al. | The different effector function capabilities of the seven equine IgG subclasses have implications for vaccine strategies | |
| CN109563169A (zh) | 抗hla-g特异性抗体 | |
| AU2018210388C1 (en) | Anti-HERV-K envelope antibody and uses thereof | |
| CN111808193B (zh) | 可结合人cd38的纳米抗体及其应用 | |
| CN112961222B (zh) | 2019新型冠状病毒n蛋白线性表位肽和单克隆抗体及应用 | |
| AU2022287551A1 (en) | Mixed binding domains | |
| CN117343182B (zh) | 抗人tigit抗体或其功能性片段及其应用 | |
| Kalinna et al. | An IgG (Fcγ,)-binding protein of Taenia crassiceps (Cestoda) exhibits sequence homology and antigenic similarity with schistosome paramyosin | |
| Willems et al. | Optimizing expression and purification from cell culture medium of trispecific recombinant antibody derivatives | |
| WO2009150539A2 (en) | Variable domains of camelid heavy-chain antibodies directed against androctonus autralis hector toxins | |
| JP2014043405A5 (https=) | ||
| CN115057939A (zh) | 结合新型冠状病毒的双特异性结合蛋白、药物和方法 | |
| CN108530534B (zh) | Nav1.9的靶点多肽、与其结合的抗体及抗体片段和相关药物组合物 | |
| EP0815141B2 (de) | Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid | |
| De Avila et al. | Mimotopes of mutalysin-II from Lachesis muta snake venom induce hemorrhage inhibitory antibodies upon vaccination of rabbits | |
| KR102406593B1 (ko) | 참나무목 식물의 꽃가루에 특이적인 항체 또는 이의 항원 결합 단편, 이를 포함한 조성물, 키트 및 이를 이용한 검출방법 | |
| US9989538B2 (en) | Monoclonal IgE antibody that binds to sweat allergy antigen protein | |
| CN117295760A (zh) | 与Fc受体结合改变的Fc突变体 | |
| CN116262784A (zh) | 增强FcRn亲和力的Fc变体 | |
| US9738702B2 (en) | Antibodies with improved half-life in ferrets | |
| US12596111B2 (en) | Means and methods for detecting soy allergens | |
| Jablonsky et al. | Purification of a mung bean protein binding to microtubules through two defined sites in the caboxyl-terminal domain of ß-tubulin |